Literature DB >> 14648647

Interspecies scaling of protein drugs: prediction of clearance from animals to humans.

Iftekhar Mahmood1.   

Abstract

The objective of this study was to evaluate the interspecies scaling for therapeutic protein drugs to predict the systemic clearance in humans from animal data. This study was undertaken to examine whether the rule of exponents of Mahmood and Balian for the prediction of clearance of nonprotein drugs can also be extended to macromolecules. Three different methods were used to predict clearance in humans: (1). clearance versus body weight (simple allometry), (2). the product of clearance and maximum life-span potential (MLP) versus body weight, and (3). the product of clearance and brain weight versus body weight. Data from 15 therapeutic proteins were analyzed, and the results indicated that the clearance of protein drugs can be predicted accurately using simple allometry or brain weight depending on the exponents of the simple allometry. Furthermore, these 15 drugs were scaled up using two species and the predicted clearance was compared with the predicted clearance obtained from more than two species. It was found that more than two species are needed for a reliable prediction of clearance. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14648647     DOI: 10.1002/jps.10531

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  23 in total

Review 1.  Fish drug analysis--Phish-Pharm: a searchable database of pharmacokinetics data in fish.

Authors:  Renate Reimschuessel; Leslie Stewart; Elizabeth Squibb; Keiko Hirokawa; Tiffany Brady; Deborah Brooks; Badar Shaikh; Clifford Hodsdon
Journal:  AAPS J       Date:  2005-09-22       Impact factor: 4.009

2.  A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics.

Authors:  Patrick Poulin
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

3.  Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.

Authors:  Aman P Singh; Wojciech Krzyzanski; Steven W Martin; Gregory Weber; Alison Betts; Alaa Ahmad; Anson Abraham; Anup Zutshi; John Lin; Pratap Singh
Journal:  AAPS J       Date:  2014-12-03       Impact factor: 4.009

Review 4.  Strategic approaches to optimizing peptide ADME properties.

Authors:  Li Di
Journal:  AAPS J       Date:  2014-11-04       Impact factor: 4.009

Review 5.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

6.  Translational considerations for cancer nanomedicine.

Authors:  Stephan T Stern; Jennifer B Hall; Lee L Yu; Laura J Wood; Giulio F Paciotti; Lawrence Tamarkin; Stephen E Long; Scott E McNeil
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

7.  Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

8.  Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.

Authors:  Leonid Kagan; Anson K Abraham; John M Harrold; Donald E Mager
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

9.  PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis.

Authors:  Nicholas E Powers; Benjamin Swartzwelter; Carlo Marchetti; Dennis M de Graaf; Alexandra Lerchner; Martin Schlapschy; Rajiv Datar; Uli Binder; Carl K Edwards; Arne Skerra; Charles A Dinarello
Journal:  J Biol Chem       Date:  2019-12-09       Impact factor: 5.157

10.  Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A.

Authors:  Priyanka Gupta; Amrita V Kamath; Summer Park; Henry Chiu; Jeff Lutman; Mauricio Maia; Man-Wah Tan; Min Xu; Lee Swem; Rong Deng
Journal:  MAbs       Date:  2016-03-31       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.